Last reviewed · How we verify
r-Hirudin
r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin.
r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin. Used for Acute coronary syndrome, Thromboembolism prevention.
At a glance
| Generic name | r-Hirudin |
|---|---|
| Also known as | Thrombexx |
| Sponsor | MinaPharm Pharmaceuticals |
| Drug class | Direct thrombin inhibitor |
| Target | Thrombin (Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
r-Hirudin is a recombinant version of hirudin, a naturally occurring anticoagulant from leech saliva. It binds directly and irreversibly to thrombin (Factor IIa), the key enzyme in the coagulation cascade, preventing thrombin from cleaving fibrinogen into fibrin and thus inhibiting clot formation. Unlike heparin, it does not require antithrombin III as a cofactor and provides more predictable anticoagulation.
Approved indications
- Acute coronary syndrome
- Thromboembolism prevention
Common side effects
- Bleeding
- Anemia
- Injection site reactions
Key clinical trials
- Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis (PHASE4)
- Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |